๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III)

โœ Scribed by Ziai, Wendy C. (author);Tuhrim, Stanley (author);Lane, Karen (author);Mcbee, Nichol (author);Lees, Kennedy (author);Dawson, Jesse (author);Butcher, Kenneth (author);Vespa, Paul (author);Wright, David W. (author);Keyl, Penelope M. (author);Mendelow, A. David (author);Kase, Carlos (author);Wijman, Christine (author);Lapointe, Marc (author);John, Sayona (author);Thompson, Richard (author);Thompson, Carol (author);Mayo, Steven (author);Reilly, Pat (author);Janis, Scott (author);Awad, Issam (author);Hanley, Daniel F. (author)

Book ID
121193874
Publisher
Blackwell Publishing Ltd
Year
2013
Tongue
English
Weight
179 KB
Volume
9
Category
Article
ISSN
1747-4930

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Results of a multicenter placebo-control
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma
โœ E. M. Lemmel; D. Brackertz; M. Franke; W. Gaus; P. W. Hartl; K. Machalke; H. Mie ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 660 KB

In a multicenter placebo-controlled double-blind randomized clinical study, 91 patients with rheumatoid arthritis were given 28 days' treatment with recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms each second day up to day 28, given by subcutaneous injection). The a